logo
logo

BeiGene partners with China’s CSPC for SYH2039

BeiGene partners with China’s CSPC for SYH2039

12/13/24, 5:06 PM
Money
$100 million
Industry
biotechnology
Type
partnership
BeiGene has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors.

Company Info

Company
BeiGene and CSPC Zhongqi Pharmaceutical Technology
Additional Info
BeiGene is a Sino-American biotech company listed on Nasdaq, and CSPC Zhongqi Pharmaceutical Technology is a Chinese company listed on the Hong Kong Stock Exchange.